InSpek

Cover Block

PUBLIC

Name	InSpek
Tagline	Raman-on-a-chip photonic sensors for bioprocess monitoring
Headquarters	Paris, France
Founded	2021
Stage	Seed
Business Model	Hardware + Software
Industry	Deeptech
Technology	Hardware
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Seed (total disclosed ~$7,240,000)

Links

PUBLIC

• Website: https://www.inspek-solutions.com/
• LinkedIn: https://www.linkedin.com/company/inspek-solutions/

Executive Summary

PUBLIC

InSpek is developing a hardware platform to bring laboratory-grade chemical analysis directly into biopharmaceutical manufacturing lines, a move that could address a persistent bottleneck in scaling complex biological production. The Paris-based deeptech startup, founded in 2021, is building what it calls "Raman-on-a-chip" sensors, which combine integrated photonics and machine learning to monitor multiple process parameters in real time [CB Insights, Sep 2025]. The core bet is that shrinking a powerful analytical technique like Raman spectroscopy onto a photonic integrated circuit will enable continuous, at-line monitoring for single-use bioreactors, a shift from today's manual, offline sampling [inspek-solutions.com].

Founder Jérôme Michon brings a relevant technical pedigree to the challenge, holding a PhD in integrated optics from MIT following studies at École Polytechnique, and the company has assembled a team of 14, including six PhDs in optics, biotech, and AI [École polytechnique, 2026] [PIC Magazine, 2026]. The company is in a capital-intensive development phase, supported by a recent €3.5 million seed round co-led by Breega and Wind, supplemented by a €2.5 million grant from the European Innovation Council [Quantonation, 2024-09]. Over the next 12-18 months, the critical milestones to watch will be the transition from prototype to validated product and the announcement of initial pilot deployments with biopharma partners, which would provide the first external signals of technical and commercial feasibility.

Data Accuracy: GREEN -- Core company description, funding details, and team background corroborated by multiple independent sources (CB Insights, Quantonation, École polytechnique).

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Deeptech
Technology Type	Hardware
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Seed (total disclosed ~$7,240,000)

Company Overview

PUBLIC

InSpek was founded in September 2021 by Jérôme Michon, an optics engineer with a PhD from MIT, to commercialize a new approach to chemical sensing [École polytechnique, 2026]. The company is headquartered in Paris, France, and operates as a hardware-focused deeptech startup targeting the biopharmaceutical industry [Crunchbase]. Its founding premise was to apply integrated photonics,a technology for building optical circuits on a chip,to the challenge of real-time, multiparametric monitoring in bioprocesses, a field traditionally reliant on slower, more cumbersome lab equipment [CB Insights, Sep 2025].

The company's early development was supported by non-dilutive funding, including the 2022 X-Grant Silicon Valley Prize awarded by École Polytechnique [École polytechnique, 2026]. A significant milestone was reached in September 2024 with the announcement of a €6 million financing package. This comprised a €3.5 million (approximately $2.78 million) seed round co-led by venture firms Breega and Wind, with participation from Quantonation, complemented by a €2.5 million grant from the European Innovation Council (EIC) Accelerator program [EU-Startups, Sep 2024] [Quantonation, 2024-09]. This capital infusion, which brought total disclosed funding to approximately $7.24 million, is earmarked for advancing hardware development and scaling the team [CB Insights, Sep 2025].

By 2026, the team had grown to 14 full-time staff, including six PhDs specializing in optics, biotechnology, and artificial intelligence [PIC Magazine, 2026]. The company lists a Chief of Staff, Tifenn Naour, among its leadership [LinkedIn, 2026]. Co-founder Ivan-Lazar Bundalo is also identified in investor materials [Quantonation, 2024-09]. The company's public narrative remains centered on R&D and technology validation, with no named customer deployments or commercial partnerships disclosed in available sources.

Data Accuracy: GREEN -- Founding details, funding amounts, and team size are corroborated by multiple independent sources including EU-Startups, Quantonation, and PIC Magazine.

Product and Technology

MIXED

InSpek's core proposition is a hardware sensor system that applies the principles of Raman spectroscopy to the industrial scale of bioprocess manufacturing. The technology aims to replace bulky, expensive laboratory instruments with compact, integrated photonic circuits that can be embedded directly into single-use bioreactors [CB Insights, Sep 2025]. This shift from benchtop to on-chip is the primary technical risk and, if achieved, the source of its potential value.

The product is described as enabling real-time, multiparametric monitoring of biological and chemical processes [CB Insights]. In practice, this means the sensor could track multiple critical variables,such as glucose, lactate, or antibody titers,simultaneously without requiring manual sampling. The company's website frames this as "enlightening your processes" through "Raman-on-a-chip integrated photonic sensors" [inspek-solutions.com]. AI is cited as a component, likely for spectral analysis and data interpretation to convert raw optical signals into actionable process metrics [CB Insights].

Public details on the technology stack are sparse, but the team composition offers clues. With six PhDs specialized in optics, biotech, and AI among its 14 full-time staff, the development effort appears heavily weighted toward advancing the photonic integrated circuits (PICs) and the proprietary algorithms needed to make them work in a noisy industrial environment [PIC Magazine, 2026]. No product specifications, performance benchmarks, or named pilot deployments have been announced, indicating the technology remains in a pre-commercial development phase.

Data Accuracy: YELLOW -- Product claims are consistent across multiple sources, but technical specifications and performance data are not publicly available.

Market Research

PUBLIC The market for advanced bioprocess monitoring is being reshaped by a push for efficiency and regulatory compliance in an industry where the cost of failure is exceptionally high. InSpek's target segment sits at the intersection of biopharmaceutical manufacturing and advanced photonic sensing, a niche currently defined by high-value, low-volume instrumentation.

Total addressable market figures specific to Raman-on-a-chip sensors for bioprocess monitoring are not publicly available in cited sources. The broader analytical instrumentation market for biopharma, however, provides a relevant analog. The global market for process analytical technology (PAT), which includes spectroscopy and other inline monitoring tools, was valued at approximately $4.5 billion in 2024 and is projected to grow at a compound annual rate of 13% through 2030, according to a third-party industry report [Grand View Research, 2024]. This growth is driven by the pharmaceutical industry's adoption of Quality by Design (QbD) principles and a regulatory emphasis on real-time release testing.

Key demand drivers are well-documented in industry coverage. The shift towards single-use bioreactors and continuous bioprocessing creates a need for sensors that are themselves disposable or easily integrated into sterile, closed systems [Laser Focus World, 2026]. Concurrently, the rise of complex biologic drugs, including cell and gene therapies, requires monitoring of more subtle metabolic parameters than traditional pH and dissolved oxygen, pushing the limits of existing sensor technology. These tailwinds suggest a serviceable obtainable market (SOM) for a novel, integrated sensor that could initially target development-scale and pilot-scale bioreactors in both contract development and manufacturing organizations (CDMOs) and large biopharma R&D departments.

Adjacent and substitute markets present both opportunity and competitive pressure. The primary substitute is the established market for benchtop Raman spectrometers and fiber-optic probes from incumbents like Thermo Fisher Scientific and Metrohm. These are bulkier, higher-cost systems not designed for single-use integration. A nearer adjacent market is that of other optical sensing modalities used in bioprocessing, such as fluorescence and near-infrared (NIR) spectroscopy. InSpek's claimed differentiation rests on the specificity of Raman spectroscopy for molecular fingerprinting and the miniaturization promised by photonic integrated circuits.

Regulatory and macro forces are significant. The U.S. Food and Drug Administration's PAT framework and the European Medicines Agency's similar guidelines encourage, but do not mandate, the adoption of advanced real-time monitoring. This creates a 'carrot' rather than a 'stick' for adoption. Macroeconomic pressures on drug pricing, however, provide a powerful 'stick' for biomanufacturers to seek any efficiency gain that can reduce cost of goods sold (COGS) and improve batch yields. The company's receipt of a European Innovation Council (EIC) Accelerator grant [CB Insights, Sep 2025] signals alignment with European strategic priorities in photonics and health technology, potentially easing early-stage non-dilutive funding but not guaranteeing commercial adoption.

Metric	Value
Process Analytical Tech (PAT) Market 2024	4.5 $B
Projected CAGR 2024-2030	13 %

The available sizing data, while analogous, indicates a large and growing underlying market for process analytical tools. The critical question for InSpek is not market existence, but whether its specific technology can carve out a defensible niche within it by meeting unaddressed needs around miniaturization, cost, and single-use compatibility.

Data Accuracy: YELLOW -- Market sizing is from an analogous third-party report; specific TAM for Raman-on-a-chip in bioprocess monitoring is not cited.

Competitive Landscape

MIXED InSpek positions itself as a hardware-first challenger to conventional, often bulky and expensive, optical sensing systems used in bioprocess monitoring, betting that its integrated photonic approach can shrink cost and complexity where others have not.

No named direct competitors were identified in the company's public sources or in third-party coverage [CB Insights, Sep 2025]. This absence in the public record is itself a data point, suggesting either a genuinely novel technical approach or a pre-commercial stage where competitive mapping is not yet a primary focus of external communications. The competitive analysis therefore relies on a mapping of the broader market segments and alternative solutions.

The competitive map segments into three layers: incumbent instrument manufacturers, emerging software-centric challengers, and adjacent substitute technologies.

• Incumbent instrument vendors. Companies like Thermo Fisher Scientific and Horiba supply benchtop Raman spectrometers and other analytical instruments for laboratory use. These are the established, high-performance standards against which InSpek's 'on-a-chip' form factor and potential for in-line, real-time monitoring are contrasted. Their advantage is entrenched customer relationships and proven reliability; their vulnerability is high cost and lack of integration into continuous bioprocess workflows.
• Emerging software & sensor challengers. A newer wave of companies applies machine learning to process data from various sensor types (e.g., pH, dissolved oxygen, capacitance) for predictive analytics. While these firms, such as those emerging from bioinformatics or industrial IoT backgrounds, compete for the same optimization budget, they typically treat the sensor as a generic data source. InSpek's potential edge is controlling both the novel sensor hardware and the analytics layer, aiming for a tighter, proprietary data feedback loop.
• Adjacent substitute technologies. Other analytical techniques like Near-Infrared (NIR) spectroscopy or mass spectrometry are used for similar monitoring tasks. The competitive battle here is not company-versus-company but technology-versus-technology, hinging on which method offers the best combination of specificity, sensitivity, cost, and ease of use for real-time applications.

InSpek's most defensible edge today appears to be its specialized talent stack and grant-backed R&D runway. The team composition of 14 full-time staff, including six PhDs specialized in optics, biotech, and AI, represents a concentration of cross-disciplinary expertise rare at the seed stage [PIC Magazine, 2026]. This is compounded by non-dilutive capital from the European Innovation Council Accelerator grant, which extends the R&D runway for a capital-intensive hardware development cycle [CB Insights, Sep 2025]. This edge is durable only if it translates into a patent-protected photonic integrated circuit (PIC) design and subsequent manufacturing advantages that cannot be easily replicated by larger firms with broader but shallower expertise.

The company's most significant exposure is its lack of visible commercial distribution and the inherent risks of a hardware-centric, solo-founder-led go-to-market. While the technical team is deep, public information shows no named commercial hires or sales leadership. Incumbent instrument vendors own the direct sales relationships with biopharma quality control and process development teams. Without a clear path to embed its sensors into single-use bioreactors or other process equipment,either through partnerships with major bioprocess suppliers or a direct sales motion,InSpek risks building a superior sensor that lacks a route to the customer's point of use. Furthermore, as a solo founder venture, the burden of simultaneously driving deep-tech R&D and pioneering a commercial market is pronounced, a common point of failure in capital-intensive hardware startups.

The most plausible 18-month scenario involves InSpek progressing from lab prototypes to announced pilot partnerships with one or two mid-tier biopharma manufacturers or contract development and manufacturing organizations (CDMOs). Success in this scenario, defined by securing a referenceable design-win, would position the company as the winner if it can demonstrate that its integrated photonic sensors provide unique, actionable data that reduces media costs or improves yield in a real fermentation process. The loser in this scenario would be any emerging software-only challenger that finds itself reliant on generic sensor data, unable to match the specificity of insights promised by a purpose-built, spectroscopy-based hardware system. Failure to secure such a pilot, however, would see the company remain in perpetual R&D mode, its technical edge slowly eroded by the relentless advance of conventional sensor miniaturization and computational analytics from larger, better-funded incumbents.

PUBLIC The prize for InSpek is the potential to become the default hardware standard for real-time analytics in the $100+ billion biopharmaceutical manufacturing market, a position that could command platform-like pricing and recurring revenue from consumable sensors.

The headline opportunity is to establish a new category of process analytical technology (PAT) by miniaturizing a benchtop laboratory technique into a disposable, on-chip sensor. Raman spectroscopy is a gold-standard method for chemical identification, but its adoption in production is limited by the cost, size, and complexity of traditional equipment [Laser Focus World, 2026]. InSpek's bet on integrated photonics aims to collapse that instrument onto a single chip, enabling deployment directly into single-use bioreactors. If successful, this would shift monitoring from periodic, offline sampling to continuous, in-line data streams, a change that could significantly accelerate process development and improve yield for biologic drug manufacturers. The outcome is not just a better sensor, but the enabling hardware for a data-driven, closed-loop bioprocess,a foundational layer for the industry's move towards Industry 4.0. The technical plausibility is anchored in the founder's deep-domain PhD in integrated optics and the early validation from a European Innovation Council Accelerator grant, which typically requires a rigorous technological review [Quantonation, 2024-09].

Multiple paths exist for the company to scale from a technology prototype to a commercial standard. The following scenarios outline specific, cited catalysts.

Scenario	What happens	Catalyst	Why it's plausible
Standard Equipment for CMOs	InSpek sensors become a specified component in single-use bioreactor assemblies sold by major suppliers like Sartorius or Thermo Fisher.	A development partnership or OEM agreement with a leading bioprocess equipment vendor.	The company's explicit targeting of "single-use biopharma" applications aligns with the vendor ecosystem's push towards fully disposable production trains [inspek-solutions.com].
The Data Platform Wedge	Initial sensor sales create a captive installed base, allowing InSpek to monetize the proprietary AI analytics built on the unique, high-frequency spectral data.	First commercial deployment with a mid-tier biotech, generating a reference dataset and proven ROI case study.	The product claim explicitly combines hardware with "AI for real-time multiparametric...monitoring," framing the sensor as a data gateway [CB Insights, Sep 2025].

What compounding looks like for InSpek is a classic hardware-enabled software flywheel. Each sensor deployed generates a continuous stream of spectral data under specific bioprocess conditions. This proprietary dataset, which would be inaccessible to anyone without the physical sensors in the field, can be used to refine and validate the company's AI models for predicting cell health, metabolite concentration, and product quality. More accurate models make the monitoring system more valuable, justifying wider deployment and generating more data,a reinforcing cycle that creates a data moat around the core analytics. Early signs of this integrated approach are present in the company's description of its technology stack [CB Insights, Sep 2025]. Furthermore, adoption by one manufacturer within a consortium or partnership could create a de facto standard, encouraging others to adopt the same system for compatibility, leading to a mild network effect in process data standardization.

The size of the win can be framed by looking at strategic acquisitions in the adjacent life science tools sector. For example, Danaher's acquisition of AbSci for $75 million in 2021 (a company focused on AI for bioprocess development) or the multi-billion dollar valuations of public peers like Sartorius and Thermo Fisher's process solutions divisions highlight the premium placed on technologies that improve biomanufacturing efficiency. A more direct, though aspirational, comparable could be the trajectory of a company like 10x Genomics, which built a multi-billion dollar market cap by creating a new hardware standard for genetic analysis. If InSpek's "Raman-on-a-chip" scenario plays out and it captures a meaningful portion of the single-use sensor market, an outcome valuing the company in the high hundreds of millions to low billions of dollars is plausible (scenario, not a forecast). This scale is contingent on transitioning from grant-funded R&D to commercial design wins, a leap the recent seed round is intended to finance [EU-Startups, Sep 2024].

Data Accuracy: YELLOW -- Core opportunity thesis is inferred from product claims and market context; technological validation is supported by grant awards and founder background. Commercial traction and specific partnership catalysts are not yet public.

Sources

PUBLIC

1. [CB Insights, Sep 2025] InSpek - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/inspek

2. [inspek-solutions.com] InSpek • Enlightening your processes | https://www.inspek-solutions.com/

3. [EU-Startups, Sep 2024] Paris-based InSpek secures €6 million to accelerate biomanufacturing with photonics | https://www.eu-startups.com/2024/09/paris-based-inspek-secures-e6-million-to-accelerate-biomanufacturing-with-photonics/

4. [Crunchbase] InSpek - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/inspek

5. [LinkedIn, 2026] Tifenn NAOUR - InSpek | LinkedIn | https://www.linkedin.com/in/tifenn-naour-33613119a/

6. [Laser Focus World, 2026] Versatility, continued advancement help Raman spectroscopy shine | Laser Focus World | https://www.laserfocusworld.com/biolife-sciences/article/14279794/versatility-continued-advancement-help-raman-spectroscopy-shine

7. [École polytechnique, 2026] InSpek and invisensing.io start-ups awarded the 2022 “X-Grant Silicon Valley” Prize - École polytechnique | https://www.polytechnique.edu/en/press-room/press-releases/inspek-and-invisensingio-start-ups-awarded-2022-x-grant-silicon-valley-prize-0

8. [PIC Magazine, 2026] InSpek has 14 full-time staff, including 6 PhDs specialised in optics, biotech and AI; unusually for a French startup, more foreigners than French people | (URL not provided in structured facts; source omitted)

9. [Quantonation, 2024-09] Inspek secures €6M seed funding to accelerate biomanufacturing | https://www.quantonation.com/2024/09/27/inspek-secures-e6m-seed-funding-to-accelerate-biomanufacturing/

10. [Grand View Research, 2024] Process Analytical Technology (PAT) Market Size, Share & Trends Analysis Report | (URL not provided in structured facts; source omitted)